Extended Data Fig. 7: Neutralizing activities in human participants receiving intranasal vaccine containing 1×1010 VPs of Ad5XBB.1.5 plus 20 μg of RBDXBB.1.5-HR protein. | Nature Biomedical Engineering

Extended Data Fig. 7: Neutralizing activities in human participants receiving intranasal vaccine containing 1×1010 VPs of Ad5XBB.1.5 plus 20 μg of RBDXBB.1.5-HR protein.

From: Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant

Extended Data Fig. 7

Participants were intranasally administered Ad5XBB.1.5 (1×1010 VPs) plus RBDXBB.1.5-HR protein (20 μg) on days 0 and 14. The neutralizing antibodies in sera collected on days 14 and 28 against pseudoviruses including prototype, BA.5, XBB.1.5, XBB.1.6, XBB.1.16, XBB.1.9.1, and XBB.2.3 were determined (n = 20 participants). Data are presented as geometric mean values with SD.

Source data

Back to article page